Left ventricular remodelling and prognosis after discharge in new-onset acute heart failure with reduced ejection fraction

Jan C. van den Berge*, Maxime M. Vroegindewey, Jesse F. Veenis, Jasper J. Brugts, Kadir Caliskan, Olivier C. Manintveld, K. Martijn Akkerhuis, Eric Boersma, Jaap W. Deckers and Alina A. Constantinescu

Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, Room Rg4, PO Box 2040, Rotterdam, 3015 GD, The Netherlands

Abstract

Aims This study aimed to investigate the left ventricular (LV) remodelling and long-term prognosis of patients with new-onset acute heart failure (HF) with reduced ejection fraction who were pharmacologically managed and survived until hospital discharge. We compared patients with ischaemic and non-ischaemic aetiology.

Methods and results This cohort study consisted of 111 patients admitted with new-onset acute HF in the period 2008–2016 [62% non-ischaemic aetiology, 48% supported by inotropes, vasopressors, or short-term mechanical circulatory devices, and left ventricular ejection fraction (LVEF) at discharge 28% (interquartile range 22–34)]. LV dimensions, LVEF, and mitral valve regurgitation were used as markers for LV remodelling during up to 3 years of follow-up. Both patients with non-ischaemic and ischaemic HF had significant improvement in LVEF (\(P < 0.001\) and \(P = 0.004\), respectively) with significant higher improvement in those with non-ischaemic HF (17% vs. 6%, \(P < 0.001\)). Patients with non-ischaemic HF had reduction in LV end-diastolic and end-systolic diameters (6 and 10 mm, both \(P < 0.001\)), but this was not found in those with ischaemic HF [+3 mm (\(P = 0.09\)) and +2 mm (\(P = 0.07\)), respectively]. During a median follow-up of 4.6 years, 98 patients (88%) did not reach the composite endpoint of LV assist device implantation, heart transplantation, or all-cause mortality, with no difference between with ischaemic and non-ischaemic HF [hazard ratio 0.69 (95% confidence interval 0.19–2.45)].

Conclusions Patients with new-onset acute HF with reduced ejection fraction discharged on optimal medical treatment have a good prognosis. We observed a considerable LV remodelling with improvement in LV function and dimensions, starting already at 6 months in patients with non-ischaemic HF but not in their ischaemic counterparts.

Keywords HFrEF; LV remodelling; Prognosis; Optimal medical treatment

Introduction

Hospitalization for new-onset heart failure (HF) often indicates a severe HF phenotype, in which introduction and titration of medication may be difficult and the response to treatment is influenced by the severity of ejection fraction impairment.\(^1\) Less is known about the natural course of patients with new-onset acute HF with reduced ejection fraction (HFrEF) who can be medically managed, but in whom the severity of left ventricular (LV) dysfunction raises the question whether advanced treatment is indicated. A too early decision for left ventricular assist device (LVAD) or heart transplantation (HT) in patients with first admission for new-onset HFrEF and who tolerate HF medication may have a heavy impact on the morbidity and mortality risks of the individual patients as well as on health...
care resources, as LV function may recover in some of these patients.²

In the current study, we aimed to investigate the LV remodelling and long-term prognosis of patients with new-onset acute HFrEF who were pharmacologically managed and survived to hospital discharge. We designed this study in patients with new-onset acute HF in order to evaluate the effect of HF medication in a formerly non-exposed patient with HF. Because the remodelling is dependent on the HF aetiology, we compared the LV remodelling between patients with ischaemic and non-ischaemic aetiology of acute HFrEF.

Methods

Study population

This retrospective cohort study consisted of patients admitted with acute HF to the Erasmus Medical Center in the period January 2008 until December 2016. The inclusion criteria were (i) a diagnosis of acute HF at admission, (ii) no history of chronic HF or any other structural heart disease, and (iii) a left ventricular ejection fraction (LVEF) < 40% at admission. Patients were excluded if they received an LVAD, underwent HT, or died before discharge and in case of limited or no follow-up in our hospital.

Our hospital is a tertiary referral centre and serves as one of the national referral centres for patients with advanced HF with need for mechanical circulatory support or HT for a significant part of the Netherlands. This study was conducted in accordance to the Declaration of Helsinki.³ Our local research ethics committee has given approval for this study.

Data collection

We extracted the variables from patients’ records and discharge letters. Data collection started at day of admission for new-onset acute HF. Follow-up was considered complete after approximately 3 years. Variables were collected during admission (i.e. baseline), at 6 months, and at 1, 2, and 3 years after admission (all ±3 months). Data collection ended when patients died, received an LVAD, underwent HT, or moved to another hospital’s outpatient clinic.

In addition to the variables age and sex, we collected body mass index, medical history, and aetiology of HF. At baseline and during follow-up moments, we gathered systolic and diastolic blood pressure, heart rate, rhythm on electrocardiogram, medical and device therapy, and a selection of laboratory parameters.

We also collected a number of echo parameters with transthoracic echocardiography. These included left ventricular end-diastolic (LVED) diameter, left ventricular end-systolic (LVES) diameter, and LVEF. The LVEF was determined by using the Simpson method with software Image-Com 5.5 (TomTec Imaging Systems GmbH, Unterschleissheim, Germany). If available, we measured the following parameters of diastolic function: E/A ratio, mitral valve deceleration time, and E/e’ ratio. The severity of mitral valve regurgitation and tricuspid valve regurgitation were classified into absent, mild, moderate, or severe. Mitral and tricuspid valve regurgitation was defined by using the qualitative and semiquantitative criteria as defined in the European Society of Cardiology guideline about valvular heart disease.⁴ Grading the severity of mitral and tricuspid valve regurgitation was performed according to the guidelines of the European Association of Echocardiography.⁵ Right ventricular function was quantified with the tricuspid annular plane systolic excursion. Lastly, we measured the inferior caval vein’s diameter.

Definitions

We defined the recovery of the LV as an LVEF of at least 50% in a patient with previous HFrEF as this definition has been used in several other studies.⁶,⁷ Furthermore, in the TRED-HF trial on withdrawal of HF medication after recovery of dilated cardiomyopathy, an improvement of LVEF to 50% was required before withdrawal was attempted.² Furthermore, we used an increase of >10% of LVEF as a measure of significant LV reverse remodelling.

Endpoint

The primary endpoint of our study was the LV remodelling during up to 3 years of follow-up. LVED diameter, LVES diameter, and LVEF were used as markers for LV remodelling. Next to those markers, we analysed the pattern of mitral valve regurgitation.

We also studied the patient’s prognosis (up to 10 years) using the composite of all-cause mortality, HT, and LVAD implantation. We also analysed the HF rehospitalization according to aetiology. The Municipal Civil Registries were consulted to assess the survival status of the included patients.

Statistical analyses

Continuous variables were presented as median with interquartile range (IQR) and categorical variables as numbers and percentages. The Mann–Whitney U test and χ² test were used to compare continuous and categorical variables, respectively.

We used the Kaplan–Meier method in order to estimate the cumulative event rates. Cox proportional hazard models were applied to evaluate the difference in the composite endpoint between patients with ischaemic and non-ischaemic aetiology of acute HF.
non-ischaemic HF. The results are presented as hazard ratio (HR) with their 95% confidence interval (95% CI).

Linear mixed-effects models were fitted for LVEF, LVED diameter, and LVES diameter (dependent) to assess remodelling. To compare remodelling between patients with ischaemic and non-ischaemic HF, we calculated the delta remodelling by subtracting the baseline measurement from the measurements taken at least 6 months after inclusion per patient, as we expected that most remodelling will have occurred within the first 6 months after admission. Subsequently, these deltas were used as dependent in the adjusted linear mixed-effects models. Lastly, Cox proportional hazard regression was used to relate the repeated LVEF, LVED, and LVES measurements to outcome. To avoid bias, parameters of the linear mixed-effects models and Cox regression models were combined in a joint model.

All tests were two-tailed, and \( P < 0.05 \) were considered as statistically significant. SPSS software (SPSS 24.0, IBM Corp., Armonk, NY, USA) was used for the descriptive statistical analyses and the survival analyses. R statistical software (Version 3.4.3) was used for the linear mixed-effects models and joint models, in particular the packages nlme and JMbayes.

**Results**

**Baseline characteristics**

During the inclusion period, 141 patients admitted with acute HF potentially qualified for inclusion. Of these, 17 patients were excluded because they died or received an LVAD before discharge, and 13 patients were excluded due to limited follow-up in our hospital. Consequently, we included 111 patients admitted with new-onset acute HF (Figure 1).

![Flow chart of patient selection. HF, heart failure; LVAD, left ventricular assist device.](image)

The included patients had a median age of 50.0 (IQR 38.6–60.3) years, almost half were men, and 38% of the patients had ischaemic HF (Table 1). Non-ischaemic HF was predominately diagnosed as idiopathic dilated cardiomyopathy \( (n = 27) \), toxic cardiomyopathy \( (n = 13) \), and myocarditis \( (n = 11) \). During admission, 48% of the patients required inotrope and/or vasopressor support, and 23% needed in addition short-term mechanical circulatory support by extracorporeal membrane oxygenation and/or intra-aortic balloon pump. Of the patients with ischaemic HF, 33 had a percutaneous coronary intervention and one underwent coronary artery bypass grafting during the initial hospitalization. At discharge, New York Heart Association class and HF treatment were comparable between patients with ischaemic and non-ischaemic HF.

**Left ventricular remodelling**

At discharge, both the LVED and LVES diameters were significantly larger in patients with non-ischaemic HF than in those with ischaemic HF (Table 2). In addition, patients with non-ischaemic HF had lower LVEF than patients with ischaemic HF \( [26\% (IQR 21–33) \text{ and } 32\% (IQR 25–36), \text{ respectively}] \). The prevalence of poor LVEF \( \text{(i.e. LVEF} \leq 30\%) \text{ at discharge} \) was higher in patients with non-ischaemic HF than in those with ischaemic HF \( (67\% \text{ vs. } 48\%, \text{ } P = 0.047) \). Furthermore, 44% of the patients exhibited moderate to severe mitral valve regurgitation, and 26% moderate to severe tricuspid valve regurgitation.

During 3 years of follow-up, LVEF recovered in 10% of the patients with ischaemic HF and in 39% of those with non-ischaemic HF \( (P < 0.001) \). Of the patients with LVEF recovery, recovery was already present in half of the patients during the echocardiographic assessment at 6 months after discharge. In total, 26% of the patients with ischaemic HF had a significant (at least 10%) improvement of LVEF, compared with 72% of those with non-ischaemic HF \( (P < 0.001) \). The LVEF recovery and significant improvement of LVEF were comparable between patients with an LVEF \( \leq 30\% \) and LVEF \( > 30\% \) \( (P = 0.06) \).

![Figure 2 presents the time-dependent changes in LVED diameter, LVED diameter, and LVEF after discharge (see Supporting Information, Table S1 for fitting values). Both patients with non-ischaemic and ischaemic HF had significant improvement in LVEF \( (P < 0.001 \text{ and } P = 0.004, \text{ respectively}) \). This improvement was significant higher in those with non-ischaemic HF \( (17\% \text{ vs. } 6\%, \text{ } P < 0.001) \). Furthermore, while patients with non-ischaemic HF had a significant reduction in LVED and LVES diameters \( (6 \text{ and } 10 \text{ mm, both } P < 0.001) \), these diameters did not change in those with ischaemic HF \( +3 \text{ mm } (P = 0.09) \text{ and } +2 \text{ mm } (P = 0.07), \text{ respectively}) \). In addition to the aforementioned parameters of LV remodelling, we also found that the severity of mitral valve

**Table 1**

| Variable | Ischaemic HF | Non-ischaemic HF |
|----------|--------------|-----------------|
| LVEF (mm) | 50 (38–60) | 32 (25–36) |
| LVED (mm) | 106 (90–120) | 122 (100–135) |
| LVES (mm) | 74 (60–80) | 86 (70–100) |

**Table 2**

| Parameter | Ischaemic HF | Non-ischaemic HF | \( P \) |
|-----------|--------------|-----------------|------|
| LVEF (%)  | 26 (21–33)   | 32 (25–36)      | <0.001 |
| LVED (mm) | 106 (90–120) | 122 (100–135)   | <0.001 |
| LVES (mm) | 74 (60–80)   | 86 (70–100)     | 0.07  |

**Supporting Information**

\[ DOI: 10.1002/ehf2.13299 \]
Table 1 Baseline characteristics of patients with ischaemic and non-ischaemic heart failure

| Demographics          | Total population (n = 111) | Ischaemic HF (n = 42) | Non-ischaemic HF (n = 69) | P-value |
|-----------------------|----------------------------|-----------------------|---------------------------|---------|
| Age                   | 50.0 (38.6–60.3)           | 58.9 (50.3–64.9)      | 43.8 (32.9–54.7)          | <0.001  |
| Male                  | 62 (56%)                   | 26 (62%)              | 36 (52%)                  | 0.32    |
| Body mass index       | 24.9 (22.3–27.3)           | 24.9 (22.7–27.2)      | 24.9 (21.8–28.0)          | 0.91    |
| **Aetiology heart failure** |                      |                       |                           | <0.001  |
| Ischaemic             |                            |                       |                           |         |
| STEMI                 | 31 (28%)                   | 31 (74%)              |                           |         |
| Non-STEMI             | 3 (3%)                     | 3 (7%)                |                           |         |
| Stable coronary artery disease | 8 (7%)                   | 8 (19%)               |                           |         |
| Idiopathic dilated cardiomyopathy | 27 (24%)             | 27 (39%)              |                           |         |
| Non-compaction cardiomyopathy | 5 (5%)                   | 5 (7%)                |                           |         |
| Hypertensive cardiomyopathy | 5 (5%)                   | 5 (7%)                |                           |         |
| Immune-mediated cardiomyopathy | 2 (2%)                   | 2 (3%)                |                           |         |
| Toxic cardiomyopathy  | 13 (12%)                   | 13 (20%)              |                           |         |
| Peripartum cardiomyopathy | 4 (4%)                   | 4 (6%)                |                           |         |
| Myocarditis           | 11 (10%)                   | 11 (16%)              |                           |         |
| Tako-tsubo cardiomyopathy | 2 (2%)                   | 2 (3%)                |                           |         |
| Medical history       |                            |                       |                           |         |
| Atrial fibrillation   | 2 (2%)                     | 1 (2%)                | 1 (1%)                    | 1.00    |
| Diabetes              | 8 (7%)                     | 7 (17%)               | 1 (1%)                    | 0.008   |
| Hypertension          | 27 (24%)                   | 19 (45%)              | 8 (12%)                   | <0.001  |
| Hypercholesterolaemia | 11 (10%)                   | 9 (21%)               | 2 (3%)                    | 0.007   |
| Smoker                |                            |                       |                           | 0.82    |
| Current smoker        | 35 (32%)                   | 16 (38%)              | 19 (28%)                  |         |
| Former smoker         | 17 (15%)                   | 7 (17%)               | 10 (15%)                  |         |
| Renal dysfunction     | 3 (3%)                     | 2 (5%)                | 1 (1%)                    | 0.57    |
| Anaemia               | 2 (2%)                     | 0 (0%)                | 2 (3%)                    | 0.51    |
| Chronic obstructive pulmonary disease | 2 (2%)                | 1 (2%)                | 1 (1%)                    | 1.00    |
| Malignancy            | 8 (7%)                     | 2 (2%)                | 7 (10%)                   | 0.13    |
| Depression            | 5 (5%)                     | 1 (2%)                | 4 (6%)                    | 0.39    |
| Advanced therapy during admission |            |                       |                           | <0.001  |
| IABP treatment        | 24 (22%)                   | 21 (50%)              | 3 (4%)                    |         |
| ECMO treatment        | 3 (3%)                     | 1 (2%)                | 2 (3%)                    | 1.00    |
| Inotrope/vasopressor support | 53 (48%)                   | 25 (60%)              | 28 (41%)                  | 0.05    |
| Characteristics at discharge |                     |                       |                           |         |
| Systolic blood pressure (mmHg) | 103 (90–115)             | 105 (88–116)        | 103 (93–115)              | 0.53    |
| Diastolic blood pressure (mmHg) | 63 (55–75)              | 65 (55–75)          | 62 (56–75)                | 0.85    |
| Heart rate (b.p.m.)   | 74 (65–83)                 | 76 (69–84)           | 72 (63–82)                | 0.19    |
| Sinus rhythm          | 101 (92%)                  | 40 (95%)             | 61 (90%)                  | 0.48    |
| Bundle branch block   |                            |                       |                           | 0.67    |
| Left bundle branch block | 5 (5%)                   | 1 (2%)                | 4 (6%)                    |         |
| Right bundle branch block | 6 (5%)                   | 2 (5%)                | 4 (6%)                    |         |
| Therapy at discharge  |                            |                       |                           |         |
| Beta-blocker          | 103 (93%)                  | 36 (86%)             | 67 (97%)                  | 0.05    |
| ACE-inhibitor or ARB  | 106 (96%)                  | 41 (99%)             | 65 (94%)                  | 0.65    |
| Mineralocorticoid receptor antagonist | 67 (60%)             | 24 (57%)             | 43 (62%)                  | 0.59    |
| Diuretics             | 97 (87%)                   | 36 (86%)             | 61 (88%)                  | 0.68    |
| Digoxin               | 55 (50%)                   | 16 (38%)             | 39 (57%)                  | 0.06    |
| Statin                | 45 (41%)                   | 39 (93%)             | 6 (9%)                    | <0.001  |
| (Direct) oral anticoagulant | 78 (70%)               | 27 (64%)             | 51 (74%)                  | 0.28    |
| Thrombocyte aggregation inhibitor | 36 (32%)          | 30 (71%)             | 6 (9%)                    | <0.001  |
| Pacemaker             | 1 (1%)                     | 0 (0%)               | 1 (1%)                    | 1.00    |
| ICD                   | 26 (23%)                   | 7 (17%)              | 19 (28%)                  | 0.19    |
| CRT                   | 4 (4%)                     | 0 (0%)               | 4 (6%)                    | 0.16    |
| Laboratory values at discharge |                |                       |                           |         |
| Creatinine (μmol/L)   | 91 (76–116)              | 94 (80–129)          | 89 (72–112)               | 0.22    |
| eGFR (mL/min)         | 64 (54–83)                | 60 (48–80)           | 67 (56–86)                | 0.11    |
| Sodium (mmol/L)       | 139 (137–141)             | 139 (137–141)        | 139 (137–141)             | 0.86    |
| Potassium (mmol/L)    | 4.5 (4.2–4.8)             | 4.5 (4.2–4.8)        | 4.5 (4.2–4.8)             | 0.85    |
| Urea (mmol/L)         | 9.2 (6.8–12.3)            | 9.3 (6.7–12.3)       | 9.2 (7.0–12.3)            | 0.82    |
| ASAT (U/L)            | 29 (23–38)                | 26 (19–33)           | 31 (25–43)                | 0.06    |
| ALAT (U/L)            | 35 (24–60)                | 26 (19–43)           | 39 (29–70)                | 0.02    |

(Continues)
regurgitation decreased during the first 6 months (P = 0.02) in patients with non-ischaemic HF but not in those with ischaemic HF (Figure 3). Furthermore, the N-terminal prohormone of brain natriuretic peptide levels decreased in both patients with ischaemic and non-ischaemic HF during follow-up, especially in the first 6 months (Table 3).

Because there was no consistent policy on the interval between the echocardiograms, we had missing values in LVED diameter, LVES diameter, and mitral valve regurgitation during the 3 years of follow-up (Supporting Information, Table S2). Nevertheless, the median number of repeated measurements for LVED diameter, LVES diameter, and LVEF was 3 (IQR 2–4).

**Prognosis**

During a median follow-up time of 4.6 years, 13 patients (12%) reached the composite endpoint of all-cause mortality, HT, and LVAD implantation. Prognosis was comparable between patients with ischaemic and non-ischaemic HF [HR 0.69 (95% CI 0.19–2.45); Figure 4]. Eleven patients died during follow-up; three patients received an LVAD, and two underwent HT. Thirteen patients (12%) needed rehospitalization for HF during the follow-up, with no difference between patients with and without ischaemic aetiology [HR 2.02 (95% CI 0.68–6.02)].

Furthermore, we found that higher increase in LVEF was associated with better prognosis [HR per 5% increase 1.13 (95% CI 1.10–1.43)]. In contrast, decreases in LVED diameter and LVES diameter were not associated with better outcome [HR per 1 mm decrease in LVED diameter 1.002 (95% CI 0.93–1.07) and HR per 1 mm decrease in LVES diameter 1.00 (95% CI 0.92–1.06)]. Adjustment for HF aetiology did not change these associations.

Among the patients with clinical follow-up until 3 years (n = 58), 28 patients received an implantable cardioverter defibrillator (ICD) and five patients of them a cardiac resynchronization therapy device. During up to 3 years of clinical follow-up, eight patients had nine shock events. Of these, four shocks were inappropriate.

After the initial hospitalization, four patients underwent cardiac surgery (three coronary artery bypass grafting and
Discussion

This study describes the LV remodelling and long-term prognosis in a cohort of patients with new-onset severe HF, who required admission and in many cases needed inotropes (48% of the patients) and short-term mechanical support (23% of the patients), but who were eventually successfully weaned from support and discharged with medication. The improvement in LVEF was already present at 6 months in the patients with non-ischaemic aetiology and increased exponentially up to 2 years of follow-up, which mirrored the decrease of LV diameters, both end-diastolic and end-systolic. Furthermore, in these patients, the severity of mitral regurgitation significantly decreased at 6 months. On the contrary, in their ischaemic counterparts, the LVEF modestly increased linearly during follow-up, while LV diameters and the severity of mitral regurgitation did not change. The prognosis of this subpopulation of patients discharged on medication after the first episode of severe acute HF is much better as compared with other studies on large cohorts with acute decompenated HF.

Indeed, it is not very unique to study recovery of LVEF and its relation with prognosis. However, our study has some unique strengths. First, we included a less heterogeneous population than others. Although other studies did not include patients with de novo HF specifically, in our opinion, LV remodelling should be studied in an early stage of HF because recovery of the LVEF takes place early. Further, compared with other studies, echocardiography in our study was repeated after a relatively short period. This enables us to say something about the trend in remodelling. Last, we included clinical variables that are missing from other studies.

Left ventricular remodelling

Improvement of LVEF in a minority of patients with dilated cardiomyopathy within 6 months and therefore deferral of listing for HT was already reported in 1994, before the introduction of beta-blocker therapy. However, after the introduction of beta-blockers and aldosterone antagonists in HF treatment, a significant improvement of LVEF was shown in one-third of patients with recently diagnosed HF, and in half of them, this improvement already occurred at 6 months. More studies have investigated improvement of LVEF and prognosis in outpatient with recent onset dilated cardiomyopathy. To the best of our knowledge, our study is the first to investigate the LV remodelling in a subpopulation of severe new-onset HF that required admission.

A large proportion of our patients received digoxin (57% of the patients with non-ischaemic HF). The beneficial properties of digoxin in acute HF syndromes have been attributed to the improvement of haemodynamics by attenuating tachycardia...
without negative inotrope effects and to the absence of side effects at lower dosages. The inotropy-dependent low-output patients in our cohort could be immediately treated with digoxin, while introduction of beta-blocker was postponed until the relief of congestion and achievement of euvolaemia, according to a previously published protocol from our centre. At discharge, >90% of patients were treated by beta-blockers in combination with ACE-inhibitors or angiotensin receptor blockers. The patients were followed weekly thereafter at our outpatient clinic, and the medication

**Figure 3** Severity of mitral valve regurgitation in patients with ischaemic (A) and non-ischaemic (B) heart failure.

**Table 3** N-terminal prohormone of brain natriuretic peptide during follow-up in patient with ischaemic and non-ischaemic heart failure

|              | Ischaemic HF | Non-ischaemic HF | P-value |
|--------------|--------------|------------------|---------|
| Baseline     | 577 (392–738)| 234 (87–401)     | 0.02    |
| 6 months     | 237 (101–514)| 48 (22–114)      | <0.001  |
| 1 year       | 170 (80–285)| 38 (18–81)       | 0.004   |
| 2 years      | 137 (79–294)| 22 (12–95)       | 0.008   |
| 3 years      | 74 (41–151)| 16 (6–124)       | 0.17    |

HF, heart failure.
Results depicted as median (interquartile range).
has been up titrated till maximum tolerated dosage according to the European Society of Cardiology HF guidelines.\textsuperscript{17}

We found a clear difference in LV remodelling between patients with non-ischaemic HF and those with ischaemic HF. This difference can primarily be explained by the aetiology of HF. To qualify for LV remodelling, there should be limited replacement fibrosis and enough viable myocardium.\textsuperscript{18} Patients with ischaemic HF are less potential to develop LV remodelling because ischaemic myocardium is more extensively and irreversibly damaged. In contrast, patients with non-ischaemic HF may have more viable myocytes.\textsuperscript{7,18} Indeed, it has been observed that some specific non-ischaemic causes like myocarditis and peripartum cardiomyopathy have a relatively high chance to recover.\textsuperscript{6} However, optimal HF treatment may be another explanation for LV remodelling. HF treatment and in particular neurohumoral blockers have been associated with LV remodelling.\textsuperscript{19,20} Optimal therapy with beta-blockers, ACE-inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists is of great importance.

In literature, several other factors, besides optimal medical treatment, have been found to be associated with LVEF improvement.\textsuperscript{9–12,14} In several studies, female sex has been associated with improvement of LV function.\textsuperscript{9–12} In our study, the distribution of sex was not different between the ischaemic and non-ischaemic HF, and we found no difference in the outcomes. However, the size of our cohort may be too small to assess the effect of sex on top of the medical treatment. The presence of hypertension and diabetes have also been correlated with LVEF changes. Furthermore, it has been reported that LVEF improvement was more common in patients with HF with non-ischaemic cause than in subjects with ischaemic HF. However, so far, the time-dependent evolution of LV remodelling including LVEF, LV dimensions, and mitral valve regurgitation has never been compared in patients with ischaemic and non-ischaemic HF.

Further, we also found a decrease in severity of mitral valve regurgitation. Decrease in mitral valve regurgitation has found to be associated with better prognosis and symptom relieve.\textsuperscript{21,22} Our study showed that LV remodelling by medical treatment also leads to reduction of mitral valve regurgitation, which is consistent with other reports.\textsuperscript{21–23}

Prognosis

The prognosis of patients with acute HF has been studied extensively. Mortality rates of up to 35% at 1 year\textsuperscript{24–28} and up to 75% at 5 years of follow-up\textsuperscript{25,27} are reported. These cohorts included patients with acute HF of the whole broad range: both new-onset acute HF and decompensated chronic HF, with and without cardiac history, and patients admitted to secondary and tertiary hospitals. Notably, our patients had a more favourable prognosis with an LVAD/HT-free survival of 88% during a follow-up of up to 10 years. The better prognosis in our study can be explained by the specific inclusion of new-onset HF in patients without a history of HF or any structural heart disease and exclusion of patients who could not be weaned from advanced support and received a permanent LVAD or died in hospital. Furthermore, we included patients in a more recent era than previous studies, and, hence, our patients were treated with the broad range of guideline-based HF medication, including a large number of patients using beta-blocker therapy.

Furthermore, we found that improvement in LVEF was associated with a better prognosis. This was in accordance with a recent meta-analysis by Jorgensen et al.\textsuperscript{29} who showed that patients in whom LVEF improved were found to have a better

**Figure 4** LVAD/HT-free survival curve of patients with ischaemic and non-ischaemic HF. HF, heart failure; HT, heart transplantation; LVAD, left ventricular assist device.

![LVAD/HT-free survival curve of patients with ischaemic and non-ischaemic HF.](image)
prognosis consisting of both improved survival rate and lower risk of appropriate ICD shocks.

Implications for clinical practice

As already mentioned, patients with HFrEF should be treated according to the guidelines with optimal dosage of beta-blocker, renin angiotensin aldosterone system inhibition, and mineralocorticoid receptor antagonists. Recently, data from the PIONEER-HF trial show that introduction of angiotensin receptor neprilysin inhibitor (ARNI) during hospitalization for acute HF significantly improved the clinical outcome as compared with ACE-inhibitors. Although not investigated in our study, replacing ACE-inhibitor by ARNI should be considered before discharge or at the outpatient clinic. Optimal medical treatment does not only carry prognostic benefit, but it may also contribute to the LV remodelling. Because we found that remodelling may occur until 2 years after the initial event mainly in non-ischaemic HF, clinicians should optimize medication and give time to remodel before concluding that LVAD or HT is necessary.

Because almost half of our study patients needed inotrope and/or vasopressor support and almost a quarter of the patients received mechanical circulatory support, this indicates that we included very ill patients with HF. Despite this adverse clinical presentation, we found remodelling in a significant part of these patients. Because we included patients with severe HFrEF with or without cardiogenic shock at presentation, part of them may currently qualify for LVAD or HT. Indeed, LVAD therapy also leads to cardiac remodelling. However, LVAD therapy has several potential complications like stroke, pump thrombosis, bleeding, and infection. Therefore, we propose persuasion of the attempts to wean the support in patients with the first hospitalization for new-onset HFrEF during concomitant optimization of HF medication. Only under the condition that patients remain inotrope dependent, one should proceed to urgent LVAD or HT.

It still remains uncertain how patients with recovered LVEF should be treated in the long term. Indeed, patients with recovered LV function may have abnormal biomarker levels and may still have an adverse long-term prognosis. Recently, the TRED-HF trial has shown that withdrawal of pharmacological treatment negatively influenced the course of dilated cardiomyopathy. In our hospital, patients with completely recovered LVEF and without HF symptoms are continued to be treated with beta-blocker and ACE-inhibitor or angiotensin receptor blocker. Basuray and Fang also advocated continuation of HF medication after recovered LVEF in patients with several different aetiologies.

Conclusions

Several study limitations should be acknowledged. First and foremost, the retrospective nature of this study resulted into a significant number of missing LVED diameters, LVES diameters, LVEF, mitral valve regurgitation, and N-terminal prohormone of brain natriuretic peptide measurements during follow-up. However, we used the delta remodelling in the linear mixed-effects models in order to make optimal use of all the available measurements. Secondly, despite the long inclusion period, we had a relatively small number of patients. This is suggesting that there are only a limited number of patients with severe new-onset HFrEF without any previous structural heart disease requiring hospitalization. Thirdly, because we are a tertiary referral centre, part of our patients initially presented in another hospital. Consequently, there may be a bias because a number of patients were not referred to our hospital, which may reduce the external validity. Next, we excluded patients who died or received an LVAD during the initial hospital admission, because we designed this study to investigate the LV remodelling in patients treated with medical HF therapy. However, this may have influenced the prognostic endpoint of this study. Furthermore, there were low implantation rates of ICD and cardiac resynchronization therapy. This could be explained by the LVEF improvement during follow-up and therefore the lack of indication for ICD. Also, the low number of events did not allow a proper multivariable analysis, because the event-per-variable ratio would lead to significant overfitting in the model and a high risk of statistical error. Lastly, we did not measure LV volumes, which could give additional information regarding LV remodelling.

We also acknowledge the lack of treatment with ARNIs and sodium-glucose co-transporter inhibitors, which were not available at the moment of our study but nevertheless may present a limitation for extrapolation of our results to the modern clinical practice.
Conflict of interest
None declared.

Funding
None.

References
1. Constantinescu AA, Caliskan K, Mainivtcel OC, van Domburg R, Jewbali L, Baik AH. Weaning from inotropic support and concomitant beta-blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis. *Eur J Heart Fail* 2014; 16: 435–443.

2. Brugts JJ, Mainivtcel O, Constantinescu A, Donker DW, van Thiel RJ, Nieman K, Jewbali LS, Zijlstra F, Caliskan K. Preventing LVAD implantation by early short-term mechanical support and prolonged inotrope therapy: a case series with acute refractory cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation and optimised medical strategy. *Neth Heart J* 2014; 22: 176–181.

3. Goodyear MD, Krleza-Jeric K, Lemmens T. The Declaration of Helsinki. *BMJ* 2007; 335: 624–625.

4. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Jung B, Lancellotti P, Lansac E, Rodriguez Munoz D, Rosenhek R, Sjogren J, Tornos M, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano J, Group ESCSD. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017; 38: 2739–2791.

5. Lancellotti P, Moura L, Pierard L, Aglicola E, Popescu BA, Tribouilloy C, Hagendorff A, Monin JL, Badano L, Zamorano J, European Association of E. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (nativ e valve disease). *Eur J Echocardiogr* 2010; 11: 307–332.

6. Basuray A, Fang JC. Management of patients with recovered systolic function. *Prog Cardiovasc Dis* 2016; 58: 434–443.

7. Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? *J Am Coll Cardiol* 2012; 60: 2465–2472.

8. Halliday BP, Wassall R, Lota AS, Khalice Z, Gregson J, Newsome S, Jackson R, Rahneva T, Wage R, Smith G, Venneri L, Tayal U, Auger D, Midwinter W, Whiffin N, Rajani R, Dungu JN, Pantesiz A, Cook SA, Ware JS, Baksi AJ, Pennell DJ, Rosen SD, Cowie MR, Cleland JGF, Prasad SK. Withdrawal of pharmacological treatment for heart failure patients with recovered dilated cardiomyopathy: the TRED-HF study; a single-blind, pilot, randomised trial. *Lancet* 2019; 393: 61–73.

9. Ghimire A, Fine N, Ezekowitz JA, Howell J, Youngson E, McAlister FA. Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. *Eur Heart J* 2019; 40: 2110–2117.

10. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, Burkman G, Siwamngsuk A, Patel A, Li S, Papadimitriou L, Butler J. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. *JAMA Cardiol* 2016; 1: 510–518.

11. Punnoose LR, Givertz MM, Lewis EF, Pratibhu P, Stevenson LW, Desai AS. Heart failure with recovered ejection fraction: a distinct clinical entity. *J Card Fail* 2011; 17: 527–532.

12. Wilcox JE, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Heywood JT, Inge PJ, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Walsh MN, Gerogeidehi M. Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. *Am Heart J* 2012; 163: 49–56.

13. Steimle AE, Stevenson LW, Fonarow GC, Hamilton MA, Morjatchi JD. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. *J Am Coll Cardiol* 1994; 23: 553–559.

14. Cicora M, Zanolla L, Latina L, Rossi A, Golia G, Brighetti G, Zarlini P. Frequency, prognosis and predictors of improvement of systolic left ventricular function in patients with ‘classical’ clinical diagnosis of idiopathic dilated cardiomyopathy. *Eur J Heart Fail* 2001; 3: 323–330.

15. McNamara DM, Starling RC, Cooper LT, Boehmer JP, Mather PJ, Janosko KM, Gorcsan J 3rd, Kip KE, Dec GW, Investigators I. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. *J Am Coll Cardiol* 2011; 58: 1112–1118.

16. Gheorghiade M, Harinistein ME, Filipptos GS. Digoxin for the treatment of chronic and acute heart failure syndromes. *Acute Card Care* 2009; 11: 83–87.

17. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoynamopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. Authors/Task Force M, Document R2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016; 18: 891–975.

18. Wilcox JE, Fonarow GC, Ardehali H, Bonow RO, Butler J, Sauer AJ, Epstein SE, Khan SS, Kim RJ, Sabbah HN, Dicz J, Gheorghiade M. “Targeting the heart” in heart failure: myocardial recovery in heart failure with reduced ejection fraction. *JACC Heart Fail* 2015; 3: 661–669.

19. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. *J Am Coll Cardiol* 2010; 56: 392–406.

20. Nijst P, Martens P, Mullens W. Heart failure with myocardial recovery—the patient whose heart failure has improved: what next? *Prog Cardiovasc Dis* 2017; 60: 226–236.

21. Stolfo D, Merlo M, Pinamonti B, Poli S, Gigli M, Barbati G, Fabris E, Di Lenarda A, Sinagra G. Early improvement of

Supporting information
Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Fitting values belonging to Figure 2.
Table S2. Number of missing values.
functional mitral regurgitation in patients with idiopathic dilated cardiomyopathy. *Am J Cardiol* 2015; **115**: 1137–1143.

22. Verhaert D, Popovic ZB, De S, Puntawangkoon C, Wolski K, Wilkoff BL, Starling RC, Tang WH, Thomas JD, Griffin BP, Grimm RA. Impact of mitral regurgitation on reverse remodeling and outcome in patients undergoing cardiac resynchronization therapy. *Circ Cardiovasc Imaging* 2012; **5**: 21–26.

23. de Groot-de Laat LE, Huizer J, Lenzen M, Spitzer E, Ren B, Geleijnse ML, Caliskan K. Evolution of mitral regurgitation in patients with heart failure referred to a tertiary heart failure clinic. *ESC Heart Fail* 2019; **6**: 936–943.

24. Harjola VP, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Hochadel M, Komajda M, Lopez-Sendon JL, Ponikowski P, Tavazzi L. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. *Eur J Heart Fail* 2010; **12**: 239–248.

25. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JW, Capewell S, McMurray JJ. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. *Circulation* 2009; **119**: 515–523.

26. Siirila-Waris K, Lassus J, Melin J, Peuhkurinen K, Nieminen MS, Harjola VP, Group F-AS. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. *Eur Heart J* 2006; **27**: 3011–3017.

27. Teng TH, Hung J, Knuiman M, Stewart S, Arnolda L, Jacobs I, Hobbs M, Sanfilippo F, Geelhoed E, Finn J. Trends in long-term cardiovascular mortality and morbidity in men and women with heart failure of ischemic versus non-ischemic aetiology in Western Australia between 1990 and 2005. *Int J Cardiol* 2012; **158**: 405–410.

28. van den Berge JC, Akkerhuis MK, Constantinescu AA, Kors JA, van Domburg RT, Deckers JW. Temporal trends in long-term mortality of patients with acute heart failure: data from 1985–2008. *Int J Cardiol* 2016; **224**: 456–460.

29. Jorgensen ME, Andersson C, Vasan RS, Kober L, Abdulla J. Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: a systematic review and meta-analyses. *Eur J Prev Cardiol* 2018; **25**: 366–376.

30. Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. *Circulation* 2019; **139**: 2285–2288.

31. Silva Enciso J. Mechanical circulatory support: current status and future directions. *Prog Cardiovasc Dis* 2016; **58**: 444–454.

32. Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, Cappola TP, Fang JC. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. *Circulation* 2014; **129**: 2380–2387.